[ad_1]
Shanghai, January 3, 2022 /PRNewswire/ – Asieris Pharmaceuticals, A global innovative pharmaceutical company focusing on new drugs for the treatment of genitourinary system tumors announced today that its oral APL-1202 combined with BeiGene’s tislelizumab as a neoadjuvant treatment for patients with muscle invasive bladder cancer has been carried out in the United States. The first patient was administered (MIBC). The investigational new drug (IND) application was approved by the US FDA and the Center for Drug Evaluation (CDE) of the National Medical Products Administration in June. China In october last year respectively.
This is an open-label, multi-center phase I/II clinical study with the following goals: assess the safety of MIBC patients; determine the recommended phase 2 dose (RP2D), and evaluate the efficacy as a neoadjuvant treatment for MIBC.
“APL-1202 combined with tislelizumab as a neoadjuvant therapy may become the best treatment option for MIBC patients. We are very pleased that the first patient received treatment in the United States,“The doctor said. Xue Yong, MD, PhD, Chief Medical Officer of Asieris. “We managed to advance the trial during the COVID-19 pandemic, which shows that not only…
The full story on Benzinga.com
[ad_2]
Source link
